The heterogeneous evolution of multidrug-resistant Mycobacterium tuberculosis
- PMID: 23245857
- PMCID: PMC3594559
- DOI: 10.1016/j.tig.2012.11.005
The heterogeneous evolution of multidrug-resistant Mycobacterium tuberculosis
Abstract
Recent surveillance data of multidrug-resistant tuberculosis (MDR-TB) reported the highest rates of resistance ever documented. As further amplification of resistance in MDR strains of Mycobacterium tuberculosis occurs, extensively drug-resistant (XDR) and totally drug-resistant (TDR) TB are beginning to emerge. Although for the most part, the epidemiological factors involved in the spread of MDR-TB are understood, insights into the bacterial drivers of MDR-TB have been gained only recently, largely owing to novel technologies and research in other organisms. Herein, we review recent findings on how bacterial factors, such as persistence, hypermutation, the complex interrelation between drug resistance and fitness, compensatory evolution, and epistasis affect the evolution of multidrug resistance in M. tuberculosis. Improved knowledge of these factors will help better predict the future trajectory of MDR-TB, and contribute to the development of new tools and strategies to combat this growing public health threat.
Copyright © 2012 Elsevier Ltd. All rights reserved.
Figures
Similar articles
-
Comparison of the socio-demographic and clinical features of pulmonary TB patients infected with sub-lineages within the W-Beijing and non-Beijing Mycobacterium tuberculosis.Tuberculosis (Edinb). 2016 Mar;97:18-25. doi: 10.1016/j.tube.2015.11.007. Epub 2015 Dec 23. Tuberculosis (Edinb). 2016. PMID: 26980491
-
Cross-sectional Whole-genome Sequencing and Epidemiological Study of Multidrug-resistant Mycobacterium tuberculosis in China.Clin Infect Dis. 2019 Jul 18;69(3):405-413. doi: 10.1093/cid/ciy883. Clin Infect Dis. 2019. PMID: 30321294 Free PMC article.
-
Mycobacterial interspersed repetitive unit typing and mutational profile for multidrug-resistant and extensively drug-resistant tuberculosis surveillance in Portugal: a 3-year period overview.Int J Antimicrob Agents. 2014 Dec;44(6):546-51. doi: 10.1016/j.ijantimicag.2014.06.021. Epub 2014 Sep 6. Int J Antimicrob Agents. 2014. PMID: 25270633
-
Drug resistance, fitness and compensatory mutations in Mycobacterium tuberculosis.Tuberculosis (Edinb). 2021 Jul;129:102091. doi: 10.1016/j.tube.2021.102091. Epub 2021 May 21. Tuberculosis (Edinb). 2021. PMID: 34090078 Review.
-
Trends in the discovery of new drugs for Mycobacterium tuberculosis therapy with a glance at resistance.Tuberculosis (Edinb). 2018 Mar;109:17-27. doi: 10.1016/j.tube.2017.12.002. Epub 2017 Dec 9. Tuberculosis (Edinb). 2018. PMID: 29559117 Review.
Cited by
-
Proteomics of multidrug resistant Mycobacterium tuberculosis clinical isolates: a peep show on mechanism of drug resistance & perhaps more.Indian J Med Res. 2015 Jan;141(1):8-9. doi: 10.4103/0971-5916.154485. Indian J Med Res. 2015. PMID: 25857490 Free PMC article. No abstract available.
-
Identifying mixed Mycobacterium tuberculosis infections from whole genome sequence data.BMC Genomics. 2018 Aug 14;19(1):613. doi: 10.1186/s12864-018-4988-z. BMC Genomics. 2018. PMID: 30107785 Free PMC article.
-
Metabolic Changes of Mycobacterium tuberculosis during the Anti-Tuberculosis Therapy.Pathogens. 2020 Feb 18;9(2):131. doi: 10.3390/pathogens9020131. Pathogens. 2020. PMID: 32085490 Free PMC article.
-
Risk Factors for Acquired Rifamycin and Isoniazid Resistance: A Systematic Review and Meta-Analysis.PLoS One. 2015 Sep 25;10(9):e0139017. doi: 10.1371/journal.pone.0139017. eCollection 2015. PLoS One. 2015. PMID: 26406228 Free PMC article. Review.
-
Accuracy of line probe assays for the diagnosis of pulmonary and multidrug-resistant tuberculosis: a systematic review and meta-analysis.Eur Respir J. 2017 Jan 18;49(1):1601075. doi: 10.1183/13993003.01075-2016. Print 2017 Jan. Eur Respir J. 2017. PMID: 28100546 Free PMC article. Review.
References
-
- World Health Organization. Global tuberculosis control - surveillance, planning, financing. Geneva: World Health Organization; 2012.
-
- Gandhi NR, et al. Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis. Lancet. 2010;375:1830–1843. - PubMed
-
- Caminero JA, et al. Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis. Lancet Infect Dis. 2010;10:621–629. - PubMed
-
- Velayati AA, et al. Emergence of new forms of totally drug-resistant tuberculosis bacilli: super extensively drug-resistant tuberculosis or totally drug-resistant strains in Iran. Chest. 2009;136:420–425. - PubMed
-
- Udwadia ZF, et al. Totally drug-resistant tuberculosis in India. Clin Infect Dis. 2012;54:579–581. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
